Free tool
FAERS Monitor: Nesina
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022271 or its brand name (Nesina, Alogliptin Benzoate). Reports on generic versions are filed under their own applications.
Reports
3,416
Serious
2,992
88% of reports
Hospitalization
1,571
Death reported
356
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea133
- nausea123
- vomiting110
- pemphigoid102
- acute kidney injury101
- rash97
- malaise93
- dyspnoea86
- blood glucose increased84
- pneumonia84
- decreased appetite80
- pruritus78
- pyrexia78
- dizziness77
- drug ineffective76
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 12 |
| 2012 | 75 |
| 2013 | 202 |
| 2014 | 272 |
| 2015 | 286 |
| 2016 | 272 |
| 2017 | 275 |
| 2018 | 339 |
| 2019 | 343 |
| 2020 | 287 |
| 2021 | 259 |
| 2022 | 186 |
| 2023 | 214 |
| 2024 | 238 |
| 2025 | 129 |
| 2026 | 27 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigoidSignal | 102 | 84.3 | 69.6 | 8,208 |
| acute kidney injurySignal | 101 | 4.1 | 3.4 | 232 |
| blood glucose increasedSignal | 84 | 2.7 | 2.2 | 92 |
| decreased appetiteSignal | 80 | 2.1 | 1.7 | 47 |
| pneumonia | 84 | 1.6 | 1.3 | 18 |
| vomiting | 110 | 1.4 | 1.2 | 15 |
| pyrexia | 78 | 1.4 | 1.1 | 8 |
| rash | 97 | 1.4 | 1.1 | 10 |
| malaise | 93 | 1.3 | 1.1 | 6 |
| diarrhoea | 133 | 1.3 | 1.1 | 8 |
| pruritus | 78 | 1.2 | 1.0 | 4 |
| nausea | 123 | 1.0 | 0.8 | 0 |
| dizziness | 77 | 1.0 | 0.8 | 0 |
| dyspnoea | 86 | 0.9 | 0.8 | 0 |
| drug ineffective | 76 | 0.4 | 0.3 | 94 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.